Nestle Says About 84% Aimmune Shares Tendered

Nestle SA (NSRGY.PK,NSTR.L) said, in an update on results of tender offer for Aimmune Therapeutics (AIMT), that about 43.44 million Aimmune shares were validly tendered. It represented about 84% of the outstanding shares of Aimmune.

The minimum tender condition to the consummation of the offer has been satisfied, Nestle

In late-August, Nestlé offered to buy Aimmune Therapeutics for $34.50 per share. The offer expired on October 9, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
Follow RTT